Related Experiment Video
Updated: Jul 28, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
Cytochrome P450 CYP1B1 activity in renal cell carcinoma
M C E McFadyen1, W T Melvin, G I Murray
1Department of Pathology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. m.mcfadyen@abdn.ac.uk
Active CYP1B1, an enzyme overexpressed in kidney cancer, was found in 70% of renal cell carcinoma (RCC) tumors. This enzyme metabolizes anticancer drugs, suggesting CYP1B1 as a potential therapeutic target for improving RCC treatment.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Renal cell carcinoma (RCC) is the most common kidney cancer with poor prognosis due to late detection and drug resistance.
- Cytochrome P450 1B1 (CYP1B1) is a P450 enzyme overexpressed in various cancers and implicated in drug resistance.
- Cytochrome P450 reductase (P450R) is essential for CYP1B1's metabolic activity.
Purpose of the Study:
- To determine the expression and activity of CYP1B1 and P450R in normal kidney and RCC tissues.
- To investigate the potential role of CYP1B1 in anticancer drug metabolism within RCC tumors.
Main Methods:
- Expression analysis of CYP1B1 and P450R in 11 paired normal and tumor kidney samples, plus 15 additional tumor samples.
- Measurement of CYP1B1 activity using the O-deethylation of ethoxyresorufin to resorufin.
- Determination of P450R activity by monitoring cytochrome c reduction.
Main Results:
- Active CYP1B1 was detected in 70% of RCC samples, with activity inhibited by the CYP1B1 inhibitor alpha-naphthoflavone.
- No CYP1B1 activity was found in any of the examined normal kidney tissues.
- Active P450R was present in all analyzed normal and tumor samples.
Conclusions:
- The presence of active CYP1B1 in a majority of RCC tumors suggests its role in drug metabolism.
- CYP1B1 represents a novel therapeutic target for intervention in renal cell carcinoma.
- Understanding CYP1B1's role could lead to strategies to overcome anticancer drug resistance in RCC.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Related Concept Videos
Inhibition of Cdk Activity
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Renal Drug Excretion: Tubular Secretion
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase